The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Anupam Rama - JPMorgan - Analyst
: Thanks both. I just want to remind folks that there are three ways to ask a question. You can raise your hand and I'll call on you. You can submit a
question in the question portal or you can email me I will start but there's a bit of a controversy out there related to the DMD program from a
regulatory perspective. And if accelerated approval is still open to players in the space after the approval of ELEVIDYS.
Question: Anupam Rama - JPMorgan - Analyst
: And then just thinking about some of the biomarker data that you're going to be getting expression, which, what would you focus the street on
and maybe like, quantify what would be a benchmark for success?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
JANUARY 15, 2025 / 11:45PM, SLDB.OQ - Solid Biosciences Inc at JPMorgan Healthcare Conference
Question: Anupam Rama - JPMorgan - Analyst
: Questions from the audience feel free?
I think you've previously stated that all the patients that are the three patients where we're going to get efficacy on are going to be around five
years of age. Actually, and I think you've stated one of the patients may have some baseline underlying cardiomyopathy.
What should we be looking for in that patient? And, and, and what could that mean in terms of differentiation for that?
Question: Anupam Rama - JPMorgan - Analyst
: Questions from the audience?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
JANUARY 15, 2025 / 11:45PM, SLDB.OQ - Solid Biosciences Inc at JPMorgan Healthcare Conference
Question: Anupam Rama - JPMorgan - Analyst
: Maybe a final question for me. But do you talked about the importance of the dual administration for SGT-212F in FA? Do you think that there's
going to be any sort of education required of the KOLS to be because of the Novel administration? Then maybe you can just speak to the gaining
factors to get into the starting that phase one.
Question: Anupam Rama - JPMorgan - Analyst
: And just quickly in 50 seconds. Gating factors to Phase Ib. Thank you.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
JANUARY 15, 2025 / 11:45PM, SLDB.OQ - Solid Biosciences Inc at JPMorgan Healthcare Conference
Question: Anupam Rama - JPMorgan - Analyst
: But we're up on time. Thank you, Bo and team.
| 
